GenMark Diagnostics, Inc.
|Company Name||GenMark Diagnostics, Inc.|
On November 2, 2017, GenMark disclosed that the administrative approval process for ePlex in Europe was taking significantly longer than expected—in some cases in excess of 180 days—which was affecting revenue generation.
On this news, GenMark’s share price fell $3.00 or approximately 41%, to close at $4.26 per share on November 3, 2017, thereby injuring investors.
Submit Your Information
If you suffered a loss on your GenMark Diagnostics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.